Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis
Brain Communications · 02.01.2026 · 8 (1)
DOI: 10.1093/braincomms/fcaf510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Communications, online erschienen am 02.01.2026. Verfasst von Chen Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15260, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institutes of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Blood-based biomarkers are crucial for individualized management of multiple sclerosis (MS). Blood neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have shown promising clinical utility in MS, but they are insufficient to guide clinical management. Plasma tau proteins remain underexplored despite the growing evidence of shared pathology in Alzheimer’s disease and MS. We aimed to: (i) assess the utility of plasma tau biomarkers [phosphorylated tau 181 (p-tau181), p-tau217 and total tau (t-tau)] in MS diagnosis, subtyping and prognosis; and (ii) compare their performance with NfL and GFAP. From a clinic-based prospective cohort, we evaluated 160 people with MS [pwMS; 117 with relapsing–remitting MS, 43 with progressive MS (PMS)] and 20 non-MS controls, all with baseline plasma samples. We measured baseline plasma concentrations of p-tau181, p-tau217, t-tau, NfL and GFAP using ultrasensitive immunoassays. We collected demographics, clinical information, and longitudinal multi-modal outcomes (Patient Determined Disease Steps, normalized age-related MS severity score, walking speed, manual dexterity, cognitive performance, retinal nerve fibre layer thickness, total brain volume and grey matter volume) over a median follow-up of 3.0 years (interquartile range, 3.5). Adjusting for demographic and clinical covariates, we evaluated associations between biomarkers and MS diagnosis, subtypes, and prognosis. We examined the enhanced value of tau markers, in addition to NfL and GFAP, for subtype distinction and outcome prediction. Participants were enrolled between 2017 and 2023. Assays were performed in August 2023. Analyses were conducted in December 2024. Participants (n = 180) had a median age of 51 years and were predominantly women (68%) and non-Hispanic white (91%). Compared with controls, pwMS had higher levels of p-tau217 (1.0 versus 0.7 pg/ml; P = 0.04) and NfL (14.1 versus 9.0 pg/ml; P < 0.01). Among pwMS, higher p-tau181 (adjusted odds ratio (aOR) [95% confidence interval (CI)] = 2.3 [1.4, 4.1]) and p-tau217 (aOR [95% CI] = 3.0 [1.8, 5.7]) were associated with PMS. These markers improved MS subtype classification accuracy beyond clinical features, NfL and GFAP. Higher baseline p-tau181 and p-tau217 predicted worse disability, functional outcomes and imaging outcomes independent of other biomarkers. Plasma p-tau181 and p-tau217 are promising biomarkers for MS subtype classification and disability prediction, providing complementary information to NfL and GFAP. Further studies to validate their potential clinical utility in guiding MS management are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
ORCID-Profile: Chen Hu, Zongqi Xia
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institutes of Neurological Disorders and Stroke
Zitieren
APA
Hu, C., Zeng, X., Zhang, L., Sehrawat, A., Powell, M., Song, E., Walker, E. L. S., Watterson, A., Zhu, W., Karikari, T. K., & Xia, Z. (2026). Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis. Brain Communications, 8(1). https://doi.org/10.1093/braincomms/fcaf510
Vancouver
Hu C, Zeng X, Zhang L, Sehrawat A, Powell M, Song E, et al. Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis. Brain Communications. 2026;8(1). doi:10.1093/braincomms/fcaf510
BibTeX
@article{Hu2026,
author = {Hu, Chen and Zeng, Xuemei and Zhang, Lili and Sehrawat, Anuradha and Powell, Megan and Song, Emily and Walker, Elizabeth L S and Watterson, Alexis and Zhu, Wen and Karikari, Thomas K and Xia, Zongqi},
title = {Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis},
journal = {Brain Communications},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/braincomms/fcaf510}
}
EUVIMED